Belatacept: the promises and challenges of belatacept and costimulatory blockade.
The publication of the belatacept phase III studies offers a challenge in balancing benefits such as reduced burden of toxicity against risks such as EBV complications and more T cell mediated rejection.
Kaplan
B
B
D000069594:Abatacept; D065095:Calcineurin Inhibitors; D017326:Clinical Trials, Phase III as Topic; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007674:Kidney Diseases / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome
D065095:Calcineurin Inhibitors; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000069594:Abatacept; D016572:Cyclosporine